Results 91 to 100 of about 58,504 (176)

Lurbinectedin plus irinotecan in pretreated gastroenteropancreatic neuroendocrine neoplasms: results of a phase II expansion cohort. [PDF]

ESMO Open
Garcia-Carbonero R, Cote GM, Le Cesne A, Antón-Pascual B, Alonso-Gordoa T, Falcon A, Gil-Torralvo A, Martínez S, Kahatt C, Alfaro V, Zubiaur P, Jimenez J, Siguero M, Molina-Cerrillo J.   +13 more
europepmc   +1 more source

Targeting FAR1 to inhibit intestinal macrophage ferroptosis: repurposing irinotecan as a novel sepsis therapy. [PDF]

Apoptosis
Deng H, Wang W, Li Q, Xiang X, Zhu Y, Zhang Z, Zhou X, Wu Y, Zhang J, Liu L, Li T.   +10 more
europepmc   +1 more source

Overcoming Irinotecan Resistance by Targeting Its Downstream Signaling Pathways in Colon Cancer

Among the most popular chemotherapeutic agents, irinotecan, regarded as a prodrug belonging to the camptothecin family that inhibits topoisomerase I, is widely used to treat metastatic colorectal cancer (CRC).
Trung Vu, Sourajeet Karfa, Zhipeng Liu, Pran K. Datta, Shashank Saurav, Temesgen Samuel, Arunima Datta, Upender Manne   +7 more
core   +1 more source

Therapeutic Effects of Ceranib-2 and Irinotecan Combination on Colon Cancer. [PDF]

Curr Issues Mol Biol
Selvi O, Vejselova Sezer C, İzgördü H, Kutlu HM.   +3 more
europepmc   +1 more source

Risk factors for irinotecan-induced hepatotoxicity: a retrospective cohort study. [PDF]

Front Oncol
Alherz FA, Alnakhli AM, Alqarni AM, Alshammari AF, Ruwayi AM, Alyamani RM, Al-Salloum H, Al-Yamani MJ, Shuweihdi F.   +8 more
europepmc   +1 more source

Acquired Chemoresistance in Colorectal Cancer: Therapy-Induced Signalling Adaptation, Cellular Plasticity and Mechanism-Guided Therapeutic Strategies. [PDF]

Cells
Bartusik-Aebisher D, Wilk I, George BP, Aebisher D.   +3 more
europepmc   +1 more source

Engineered human adipose-derived stem cells delivering carboxylesterase and TRAIL for castration-resistant prostate cancer: Translational synthesis. [PDF]

Investig Clin Urol
Kim JH, Lee SH, Song YS.
europepmc   +1 more source

Long-Term Response and Survival With Liposomal Irinotecan and Fluorouracil in a Patient With Locally Advanced Pancreatic Ductal Adenocarcinoma: A Case Report. [PDF]

Cureus
Tulyte-Kirzova S, Vitkauskaite E, Gumbys L.   +2 more
europepmc   +1 more source

Efficacy and safety of liposomal irinotecan plus nimotuzumab in immune checkpoint inhibitor-refractory recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase II trial. [PDF]

EClinicalMedicine
He S, Bei WX, Lu N, Zhao ZY, Ye Y, Chen C, Tang L, Liu L, Lv S, Xiang YQ, Wang L.   +10 more
europepmc   +1 more source

Impact of prior conventional irinotecan use on nanoliposomal irinotecan efficacy in advanced pancreatic cancer: a meta-analysis. [PDF]

ESMO Open
Lee S, Correa TL, Birda V, Roshan K, Peters ML, Modest AM, Keko M, Bockorny B.   +7 more
europepmc   +1 more source